Long-term entecavir treatment reduces hepatocellular carcinoma incidence in patients with hepatitis B virus infection†
Version of Record online: 6 MAR 2013
Copyright © 2012 American Association for the Study of Liver Diseases
Volume 58, Issue 1, pages 98–107, July 2013
How to Cite
Hosaka, T., Suzuki, F., Kobayashi, M., Seko, Y., Kawamura, Y., Sezaki, H., Akuta, N., Suzuki, Y., Saitoh, S., Arase, Y., Ikeda, K., Kobayashi, M. and Kumada, H. (2013), Long-term entecavir treatment reduces hepatocellular carcinoma incidence in patients with hepatitis B virus infection. Hepatology, 58: 98–107. doi: 10.1002/hep.26180
Potential conflict of interest: Hiromitsu Kumada has received speaker's honoraria from Bristol-Myers Squibb. None of the other authors have a conflict of interest to disclose.
- Issue online: 24 JUN 2013
- Version of Record online: 6 MAR 2013
- Accepted manuscript online: 5 DEC 2012 02:51AM EST
- Manuscript Accepted: 15 NOV 2012
- Manuscript Received: 26 APR 2012
Additional Supporting Information may be found in the online version of this article.
|HEP_26180_sm_SuppFig1.eps||1084K||Supporting Information Figure 1. Histogram of propensity score logit showing the overlap between the ETV and control group.|
|HEP_26180_sm_SuppFig2.eps||881K||Supporting Information Figure 2. Standardized differences before and after propensity score matching comparing covariate values for patients treated with or without ETV.|
|HEP_26180_sm_SuppTables.doc||92K||Supporting Information Tables|
Please note: Wiley Blackwell is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.